Synthetic peptide
ARA-290
An investigational erythropoietin-derived peptide studied for neuropathic pain and tissue protection.
- Sequence
- Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
- Formula
- C51H84N16O21
- Molecular weight
- 1257.4 Da
Evidence confidence
Human
5/5
Strong human clinical evidence
3 citations
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
3/5
Reasonable safety characterisation
3 citations
Claimed uses
- Moderate
- Moderate
Mechanisms
Safety notes
Short studies suggest acceptable tolerability, but long-term safety and effectiveness are not established. Unregulated products may not contain authentic peptide.
Regulation
- Clinical-stage investigational peptide without general approval for neuropathy treatment.
- Not approved as a medicine for neuropathy in major regulated markets. Cibinetide remains investigational.
References
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes · 2015
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density · 2013
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study · 2012
Last reviewed
12 July 2026